Alzheimer’s disease, mAb drugs, cross-sectional compare
Abstract
Alzheimer’s disease (AD), as a serious chronic neurological disease, has brought tremendous pressure to global health.This devastating disease primarily impairs cognitive abilities and causes most people with dementia. Current treatments, including acetylcholinesterase inhibitors (AChEI) and anti-amyloid monoclonal antibodies (mAbs), offer limited effectiveness. In later a long time, monoclonal antibodies have risen as treatments for Ad, with encouraging results in reducing amyloid accumulation and alleviating clinical manifestations. This article reviews the latest development of mAb-based AD drugs, with emphasis on aducanumab, lecanemab and donanemab. A comparative investigation of clinical trials assessed the viability and security of these monoclonal antibodies in cognitive decay, utilitarian capacity, and generally quality of life. mAbs targeting Aβ deposition such as aducanumab and lecanemab developed for Aβ deposition are designed to clear or reduce these deposits in the brain to potentially slow the rate of AD progression. The instrument of activity of mAb in Ad treatment, such as crossing the blood-brain obstruction, official to the Aβ target and advancing its clearance, is additionally talked about. This article proposes the potential of monoclonal forebear within the administration of Ad, but recognizes the require for thorough advantage and hazard evaluation of important security prove.
